Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
September 16 2024 - 7:30AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2024
Commission File Number: 001-34563
CONCORD MEDICAL SERVICES HOLDINGS LIMITED
Room A1-A5 26/F, East Zone, Hanwei Plaza
No. 7 Guanghua Road, Chaoyang District,
Beijing 100020
People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F
x Form 40-F ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Exhibit Index
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
CONCORD MEDICAL SERVICES HOLDINGS LIMITED |
|
|
|
|
By: |
/s/ Jianyu Yang |
|
Name: |
Jianyu Yang |
|
Title: |
Chairman and Chief Executive Officer |
Date: September 16, 2024
Exhibit 99.1
Concord Medical Announces Obtaining Large Medical
Equipment Procurement License
for Its Proton Therapy Equipment
BEIJING, September 16, 2024 /PRNewswire/
-- Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider
specialized in cancer treatment, research, education and prevention in China, today announced that Guangzhou Concord Cancer Center (“Guangzhou
Hospital”), a PRC subsidiary of the Company offering comprehensive cancer care services, has obtained the large medical equipment
procurement license (the “License”) for its proton equipment.
As
previously disclosed in the Company’s annual report for the fiscal year ended December 31, 2023, Guangzhou Hospital has completed
the installment of the proton equipment in September 2020 and commenced its clinical trial in November 2022. Guangzhou Hospital
has also subsequently submitted the application for the License for such proton equipment, planning to offer proton therapy treatment
services at its proton center. On September 14, 2024, the National Health Commission of the PRC announced to grant approval
to Guangzhou Hospital’s application for the License. Guangzhou Hospital plans to start its proton therapy treatment services at
its earliest convenience after necessary preparations.
Concord Healthcare Group Co., Ltd. (“Concord
Healthcare”), a subsidiary of the Company listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “HKSE”)
under the stock code 2453.HK, also announced on September 15, 2024 that Guangzhou Hospital had obtained the License. The Company
previously announced the listing of Concord Healthcare’s H shares on the HKSE on January 9, 2024. The information related to
Concord Healthcare’s Transactions on the HKSE is accessible through the HKSE’s website at www.hkexnews.hk.
About Concord Medical
Concord Medical Services Holdings Limited is a
healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention.
The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals
and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving
to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered
hospitals across China. For more information, please see http://ir.ccm.cn.
About Concord Healthcare
Concord Healthcare is an oncology healthcare provider
in China. Concord Healthcare serves both cancer patients through self-owned medical institutions and third-party medical institutions
through medical equipment, software and related services. In its self-owned medical institutions, Concord Healthcare provides a full
spectrum of oncology healthcare services to cancer patients across the entire care continuum, leveraging its multidisciplinary team specialists
and diagnosis and treatment capabilities featuring precision radiation therapy. Through its medical equipment, software and related
services, Concord Healthcare serves a widespread network of enterprise customers, primarily hospitals, with integrated oncology-related
services, including primarily sales and installing of medical equipment and software, management and technical support, and operating
lease.
Safe Harbor Statement
This announcement contains forward-looking statements.
These forward-looking statements can be identified by words or phrases such as “will,” “expects,” “anticipates,”
“future,” “intends,” “plans,” “believes,” “estimates” and similar expressions.
Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company’s control and based upon
premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results
to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
For more information, please contact:
Concord Medical Services Holdings Limited
Investor Relations
+86 10 5903 6688
ir@ccm.cn
Concord Medical Services (NYSE:CCM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Concord Medical Services (NYSE:CCM)
Historical Stock Chart
From Dec 2023 to Dec 2024